Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2 (CNTRACS 2)

5 november 2026 uppdaterad av: Deanna Barch, Washington University School of Medicine

Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium

In Study 2, investigators will recruit individuals with schizophrenia (SZ) and or schizoaffective disorder (SZA) and healthy controls (HC) using optimized behavioral tasks to replicate the behavioral findings from Study 1 and to assess additional psychometric properties such as test re-test reliability and practice effects.

Investigators will obtain data on: A) clinical symptoms, with detailed assessment of hallucinations and delusions; B) community functioning; and C) functional capacity, allowing us to examine clinical validity. To generate a sample with sufficient variation in hallucinations and delusions, investigators will recruit the following groups that balance feasibility with clinical relevance: A) healthy controls [HC, N=125]; B) schizophrenia and schizoaffective disorder [SZ/SZA, N=200]). Investigators anticipate a ~20% screen fail/drop-out rate based upon prior studies. Thus, investigators will run an additional 40 SZ/SZA and 15 HC.

Investigators will administer tasks optimized in Aim 1 without electroencephalogram (EEG), to this new sample of individuals with SZ/SZA and HC.

All participants will be retested after approximately 28 days and repeat clinical assessments. Although the investigators' goal is to shorten task length using the Study 1 analyses, they will administer longer tasks than optimal for public dissemination in Study 2 to determine the minimum number of trials required for acceptable reliability. Study 2 will use the same clinical and functional measures as Study 1.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Each participant will complete 3 sessions (~3 hours each) within 3 weeks at baseline. The first session includes clinical, self-report, proxy function, and community function assessments. Sessions 2-3 are for task. Each participant will complete 7 tasks across these sessions. Task order will be counterbalanced across sessions. Participants will return after 28 days and repeat these same 3 sessions.

Clinical Assessment and Self-Report: A trained assessor will diagnose participants using the Structured Clinical Interview (SCID-5) for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Text Revision 59 (TR59). Clinicians will rate hallucination and delusion symptom severity with the Chicago Hallucinations Assessment Tool (CHAT) and the Brief Psychiatric Rating Scale (BPRS). Investigators will use the Psychotic Symptom Rating Scales (PSYRATS) to evaluate the degree of preoccupation, conviction, distress, and life disruption associated with hallucinations and delusions elicited on the BPRS and CHAT. To address specificity, investigators will administer the Clinical Assessment Interview for Negative Symptoms (CAINS). For self-report, investigators will use the Beliefs about Voices Scale which assesses attributions about the origin and power of voices, and the Yale Control Over Perceptual Experiences (COPE) scale, which evaluates the extent to which people feel they can exert control over their voices. Investigators also will use the Peters Delusion Inventory to assess the extent of delusional thinking, supplemented by the Green Paranoia Scale to provide additional coverage of persecutory beliefs. To assess specificity, investigators will use the Patient Health Questionnaire (PHQ-9) to assess depression, the Generalized Anxiety Disorder Scale (GAD-7) to assess anxiety, and the Motivation and Pleasure Scale-Self-Report (MAP-SR) to assess anhedonia and motivation. Investigators will conduct a principal components analysis (PCA) on measures of the same construct (e.g., delusions) and perform primary analyses using the first principal component, followed by secondary analyses of specific measures False Discovery Rate (FDR) correction.

Community Function: Patients will complete the Specific Levels of Functioning (SLOF) scale, a validated scale of work and community function. National Institute of Mental Health (NIMH) Common Data Elements: Investigators will acquire the additional NIMH Tier 1 Common Data elements (e.g., World Health Organization Disability Assessment Schedule 2 (WHODAS 2.0) & DSM-5 Symptom Measure). Investigators will include standard general cognitive measures to assess the specificity of effects beyond general cognitive impairment. Specifically, investigators will include validated online measures from TestMyBrain (https://www.testmybrain.org/using-tmb/research.html; Digit Symbol Coding, Vocabulary, and Matrix Reasoning), as in our prior work in both clinical and healthy populations.

Studietyp

Interventionell

Inskrivning (Beräknad)

325

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Deanna Barch, Ph.D.
  • Telefonnummer: 314-935-8729
  • E-post: dbarch@wustl.edu

Studera Kontakt Backup

Studieorter

  • Förenta staterna
    • California
      • Irvine, California, Förenta staterna, 92868
        • University of California Irvine
        • Kontakt:
    • Illinois
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21201
        • University of Maryland, Baltimore
        • Kontakt:
    • Minnesota
      • Minneapolis, Minnesota, Förenta staterna, 55455
        • University of Minnesota
        • Kontakt:
          • Angus Macdonald III, PhD
          • Telefonnummer: 612-624-3813
          • E-post: angus@umn.edu
        • Kontakt:
    • Missouri
      • St Louis, Missouri, Förenta staterna, 63110
        • Washington University
        • Kontakt:
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 59 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

General Inclusion

  • age 18 to 59 ;
  • no substance disorder in past six months (confirmed with urine drug screens and breathalyzers);
  • no clinically significant head injury or neurological disease;
  • WechslerTest of Adult Reading (WTAR) score =16+.

Group Specific Criteria: Schizophrenia/SchizoaffectiveDisorder (SZ/SZA):

  • Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnosis ofschizophrenia or schizoaffective;
  • no medication changes in prior month or anticipated in the next month or not taking medications;
  • outpatient or partial hospital if unmedicated
  • Healthy Controls (HC):
  • no Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) - Psychosis or BipolarDisorder;
  • no family history of psychosis or bipolar

Exclusion Criteria:

Healthy Controls (HC):

  • Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)Psychosis or Bipolar Disorder diagnosis
  • Family history of psychosis, bipolar, or Schizophrenia/Schizoaffective Disorder (SZ/SZA)

additional exclusion criteria for the unmedicated individuals are:

  • not in acute exacerbation requiring immediate hospitalization or treatment;
  • self-reported medication non-compliance for at least the four previous weeks
  • never having started medications

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Sine Wave Speech Task Performance
Tidsram: 1 hour

Percentage of trials coded as speech or not vs Dprime
1 hour
Volatility Task Performance
Tidsram: 1 hour

Percent correct bag captures during periods of stability vs. instability - patients worse in both, but particularly impaired in instability vs. Environmental volatility belief parameter
1 hour
Minnesota Trust Game Performance
Tidsram: 1 hour

Percent of trusting choices depending on decision-agent and temptation vs. spite-guilt beliefs estimate
1 hour
Dynamic Trust Game Performance
Tidsram: 1 hour

Trust indexed by mean investment versus learning rates
1 hour
Motion Perception Task Performance
Tidsram: 1 hour

With 15 degrees of initial or changed direction vs. the probability of failing to update
1 hour
Kamin Blocking Task Performance
Tidsram: 1 hour

Number of times participant predict allergy following blocked cue vs. prediction errors and learning rates
1 hour
Choice Probabilistic Reversal Performance Task
Tidsram: 1 hour

Win-switch rate (higher in patients, particularly paranoid patients) vs. (prior on volatility belief updating in response to volatility
1 hour

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Washington University School of Medicine

Samarbetspartners

National Institute of Mental Health (NIMH)
University of Chicago
University of Minnesota
University of California, Irvine
University of Maryland, Baltimore County

Utredare

  • Huvudutredare: Deanna Barch, PhD, Washington University School of Medicine

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 april 2028

Primärt slutförande (Beräknad)

30 juni 2031

Avslutad studie (Beräknad)

30 juni 2031

Studieregistreringsdatum

Först inskickad

8 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

8 oktober 2026

Första postat (Faktisk)

15 oktober 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 201904012: Study 2
  • 2R01MH084840 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Our plan is to share de-identified participant data through the National Data Archive (NDA) as required by the National Institute of Mental Health (NIMH)

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera